Piracetam Shields Rat Lungs From Cyclophosphamide Damage by Dampening Inflammasome and Apoptosis Pathways

Cyclophosphamide is one of the workhorses of modern medicine. It is used against a wide range of cancers and autoimmune disorders, and it works by cross-linking DNA, which cuts DNA synthesis and cell replication, especially in fast-dividing cells. The same drug can also harm tissue it was never meant to touch. The lungs are among the most vulnerable, and that vulnerability limits how freely the drug can be used.

The damage is well described. Cyclophosphamide injury in the lung can appear as pneumonitis, pulmonary fibrosis and destruction of the alveoli, and it can progress to respiratory failure. The liver breaks the drug down into two products, phosphoramide mustard and acrolein. Phosphoramide mustard is tied to the therapeutic effect. Acrolein is tied to the harm: it impairs the cell's antioxidant defenses and drives up reactive oxygen species. Those species damage DNA, lipids and proteins, and they switch on NF-κB, a signaling molecule that turns on inflammatory genes, including the NLRP3 inflammasome, TNF-α, IL-18 and IL-1β.

NLRP3 sits at the center of the chain. It pairs with procaspase-1 to form a complex that produces active caspase-1. Caspase-1 matures IL-1β and IL-18 and also cleaves gasdermin D, which opens large pores in the cell membrane and triggers a form of cell death called pyroptosis. NF-κB also feeds the production of caspase-3, an executioner of apoptosis. A third player, AMPK, an enzyme that regulates energy metabolism, has been shown to protect against sepsis-induced lung injury. The authors note that few studies have examined its role in cyclophosphamide lung damage.

A research team set out to test whether piracetam, a drug better known as a nootropic, could interrupt that chain. Piracetam is a cyclic derivative of GABA, is well tolerated, and has no documented irreversible side effects. It is used for dyslexia, vertigo, age-related cognitive disorders and chemotherapy-related cognitive impairment. Earlier rat work gave the team reason for hope. In a cyclophosphamide liver model, piracetam inhibited NLRP3-driven pyroptosis and caspase-3 apoptosis. In a cisplatin kidney model, it dampened NF-κB/p38 MAPK signaling and raised AMPK. The authors say no one had yet tested it against cyclophosphamide in the lung.

The experiment used 40 male Wistar rats, 7 to 9 weeks old and weighing 180 to 200 grams, split into four groups of ten. One group got saline for 15 days. One got piracetam alone, 300 mg/kg daily by gavage. One got a single intraperitoneal dose of cyclophosphamide, 200 mg/kg, on day 12. The last got both: piracetam for 15 days plus the cyclophosphamide dose on day 12. All 40 animals survived. Analyses covered six rats per group, 24 in all, and Western blotting and immunohistochemistry used a subset of three per group. The other four per group were frozen at minus 80 °C for future work. The protocol was approved by the ethics committee at Deraya University in Egypt.

The team also ran molecular docking to predict how piracetam might bind NF-κB p65, NLRP3, caspase-1, caspase-3 and AMPK, and reported favorable binding affinities for all of them.

Cyclophosphamide alone did measurable harm. Arterial oxygen (PaO₂) fell and carbon dioxide (PaCO₂) rose, a sign of impaired gas exchange. Lung levels of MDA, a marker of lipid damage, rose, along with IL-18, IL-1β, TNF-α, caspase-1 and the pro-apoptotic gene Bax. Antioxidant GSH, catalase, p-AMPK and the protective gene Bcl-2 fell. NLRP3 protein was upregulated, and NF-κB p65 and caspase-3 staining intensified.

Piracetam pretreatment markedly improved these functional, biochemical and tissue-level abnormalities, according to the authors. The protection was associated with suppression of NF-κB/NLRP3/caspase-1 and caspase-3 signaling and with higher p-AMPK. The work is preclinical, in a small number of rats, and any use of piracetam to protect patients' lungs during chemotherapy would first require human trials.